These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26498748)

  • 1. Piloting prostate cancer patient-reported outcomesin clinical practice.
    Korzeniowski M; Kalyvas M; Mahmud A; Shenfield C; Tong C; Zaza K; Howell D; Brundage M
    Support Care Cancer; 2016 May; 24(5):1983-1990. PubMed ID: 26498748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot evaluation of the expanded prostate cancer index composite for clinical practice (EPIC-CP) tool in Ontario.
    Brundage MD; Barbera L; McCallum F; Howell DM
    Qual Life Res; 2019 Mar; 28(3):771-782. PubMed ID: 30382479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An observational study evaluating the impact on prostate patient outcomes and experiences when radiation therapists use a standard grading system tool to assess and document treatment-related toxicities and interventions.
    Leung E; Fineberg H; Larsen T; Yaver M; Foo A; Ma J; Versloot J; Minotti SC
    J Med Imaging Radiat Sci; 2022 Sep; 53(3):444-452. PubMed ID: 35850922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain.
    Zapatero A; Maldonado Pijoan X; Gómez-Caamaño A; Pardo Masferrer J; Macías Hernández V; Hervás Morón A; Muñoz García JL; Palacios Eito A; Anguita-Alonso P; González-Junco C; López Torrecilla J
    Health Qual Life Outcomes; 2021 Sep; 19(1):223. PubMed ID: 34563208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Use of Expanded Prostate Cancer Index Composite for Clinical Practice to Assess Patient Reported Prostate Cancer Quality of Life Following Robot-Assisted Radical Prostatectomy.
    Wagner AA; Cheng PJ; Carneiro A; Dovirak O; Khosla A; Taylor KN; Crociani CM; McAnally KC; Percy A; Dewey LE; Sanda MG; Chang P
    J Urol; 2017 Jan; 197(1):109-114. PubMed ID: 27475967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
    Wei JT; Dunn RL; Litwin MS; Sandler HM; Sanda MG
    Urology; 2000 Dec; 56(6):899-905. PubMed ID: 11113727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilizing Digital Health to Collect Electronic Patient-Reported Outcomes in Prostate Cancer: Single-Arm Pilot Trial.
    Tran C; Dicker A; Leiby B; Gressen E; Williams N; Jim H
    J Med Internet Res; 2020 Mar; 22(3):e12689. PubMed ID: 32209536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross validation of the prostate cancer radiotherapy late toxicity (PCRT) questionnaire with the expanded prostate cancer index composite (EPIC) instrument.
    Rodrigues G; Bauman G; Venkatesan V; Ahmad B; Lock M; Sexton T; D'Souza D; Stitt L; Eid S
    Can J Urol; 2011 Aug; 18(4):5802-10. PubMed ID: 21854712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding.
    Lee JY; Daignault-Newton S; Heath G; Scarlett S; Sanda MG; Chang P; Regan MM; Michalski JM; Sandler HM; Feng FY; Kuban DA; Zietman AL; Ciezki JP; Kaplan ID; Crociani C; McLaughlin WP; Mantz CA; Finkelstein SE; Suy S; Collins SP; Garin O; Ferrer M; Hamstra DA; Spratt DE
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):770-777. PubMed ID: 27663760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors.
    Szymanski KM; Wei JT; Dunn RL; Sanda MG
    Urology; 2010 Nov; 76(5):1245-50. PubMed ID: 20350762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer.
    Chang P; Szymanski KM; Dunn RL; Chipman JJ; Litwin MS; Nguyen PL; Sweeney CJ; Cook R; Wagner AA; DeWolf WC; Bubley GJ; Funches R; Aronovitz JA; Wei JT; Sanda MG
    J Urol; 2011 Sep; 186(3):865-72. PubMed ID: 21788038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and pilot-testing of the expanded prostate index composite - Filipino version (EPIC-F).
    Bacorro W; Tordesillas D; Dumago M; Trogo JD; Mendoza E; Alpajaro SI; Arcinas R; Fajilan W
    Asia Pac J Clin Oncol; 2023 Aug; 19(4):517-524. PubMed ID: 36464927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer.
    Shaikh T; Li T; Handorf EA; Johnson ME; Wang LS; Hallman MA; Greenberg RE; Price RA; Uzzo RG; Ma C; Chen D; Geynisman DM; Pollack A; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):722-731. PubMed ID: 28244407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice.
    Chipman JJ; Sanda MG; Dunn RL; Wei JT; Litwin MS; Crociani CM; Regan MM; Chang P;
    J Urol; 2014 Mar; 191(3):638-45. PubMed ID: 24076307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments.
    Vertosick EA; Vickers AJ; Cowan JE; Broering JM; Carroll PR; Cooperberg MR
    J Urol; 2017 Sep; 198(3):671-677. PubMed ID: 28342935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer.
    Einstein DJ; Patil D; Chipman J; Regan MM; Davis K; Crociani CM; Wagner AA; Sanda MG; Chang P
    Urology; 2019 May; 127():53-60. PubMed ID: 30790648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychometric Assessment of the Chinese Version of the Abbreviated Expanded Prostate Cancer Index Composite (EPIC-26) and the Clinical Practice Version (EPIC-CP) in Chinese Men With Prostate Cancer.
    Lam WWT; Tse MA; Ng CNL; Chung EKM; Fielding R
    J Pain Symptom Manage; 2017 Jun; 53(6):1085-1090. PubMed ID: 28438583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient preferences for reducing bowel adverse events following prostate radiotherapy.
    Mishra MV; Thayer WM; Janssen E; Hoppe B; Eggleston C; Bridges JFP
    PLoS One; 2020; 15(7):e0235616. PubMed ID: 32639983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Quality of life in patients with prostate cancer: validation of an instrument for clinical practice].
    Balbontín F; Marchetti P; Moreno S; Cabello JM; Urzúa C; Silva A; Avilés J; Badínez L; García J; Salgado A; Vinez E; Alliende I; Canals A; Velasco A
    Arch Esp Urol; 2015 Jun; 68(5):466-73. PubMed ID: 26102050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes and health-related quality of life in prostate cancer treated with a single fraction of high dose rate brachytherapy combined with hypofractionated external beam radiotherapy.
    Choudhury A; Arthur C; Malik J; Mandall P; Taylor C; Alam N; Tran A; Livsey J; Elliott T; Davidson S; Logue JP; Wylie J
    Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):661-7. PubMed ID: 25027670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.